A Polypill Strategy to Improve Adherence

José M. Castellano, Ginés Sanz, José L. Peñalvo, +21

Journal of the American College of Cardiology

Non-pharmacological InterventionPreventive MedicineHealth PolicyTreatment And PreventionHealth Promotion +5

CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies

Valentín Ortiz‐Maldonado, Susana Rives, María Castellà, +37

Molecular Therapy

TET2 Mutations Are Associated with Specific 5-Methylcytosine and 5-Hydroxymethylcytosine Profiles in Patients with Chronic Myelomonocytic Leukemia

Cristina Pérez, Nicolás Martínez‐Calle, José I. Martı́n-Subero, +14

PLoS ONE

Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study

Aina Oliver‐Caldés, Verónica González‐Calle, Valentín Cabañas, +28

The Lancet Oncology

Hematological MalignancyMedicineImmunologyHematologyInitial Infusion +5

Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients

Miguel Caballero‐Baños, Daniel Benítez‐Ribas, Jaime Tabera, +14

European Journal of Cancer

Surgical OncologyOncologyPhase IiColorectal CancerPathology +4

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura

Cristina Pascual, María Eva Mingot‐Castellano, A Fuentes, +37

Blood Advances

Economic impact of an electronic alert system to prevent venous thromboembolism in hospitalised patients

Ramón Lecumberri, Elena Panizo, A. GOMEZ‐GUIU, +7

Journal of Thrombosis and Haemostasis

ThrombosisVenous ThrombosisHealth PolicyRemote Patient MonitoringPatient Safety +13

Growth hormone protects against radiotherapy-induced cell death

Olga Madrid, Sara Varea, Isabel Sánchez‐Pérez, +4

European Journal of Endocrinology

The academic point‐of‐care <scp>anti‐CD19</scp> chimeric antigen receptor T‐cell product varnimcabtagene autoleucel (<scp>ARI</scp>‐0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B‐cell <scp>non‐Hodgkin</scp> lymphoma

Núria Martínez‐Cibrián, Valentín Ortiz‐Maldonado, Marta Español‐Rego, +31

British Journal of Haematology

Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

Aina Oliver‐Caldés, Marta Español‐Rego, Aintzane Zabaleta, +37

Clinical Cancer Research